

SPECIALTY QUANTITY LIMIT PROGRAM

VITRAKVI (larotrectinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Vitrakvi 25 mg capsules	180 per 30 days	<ul style="list-style-type: none"> • Adult dosing: 100 mg twice daily • Pediatric dosing: 100 mg/m², not to exceed 100 mg, twice daily • Dose modifications for adverse reactions and drug interactions: dose reduction by 25% to 75% may be required.
Vitrakvi 100 mg capsules	60 per 30 days	
Vitrakvi oral solution (20 mg/mL) 100 mL bottle	300 mL (3 bottles) per 30 days	

III. REFERENCES

- Vitrakvi [package insert]. Stamford, CT: Loxo Oncology, Inc.; July 2019.